Recipharm’s fifteen facilities are now fully prepared for drug serialization and have delivered serialized batches within Europe ahead of the February 9th deadline.

During the period 2016-2018, the company invested €35 million into its operations and launched a three-year program to provide a compliant serialization, ahead of the introduction of the EU Falsified Medicines Directive (EU FMD) and the US Drug Supply Chain Security Act (DSCSA). All of the facilities are connected to customers to allow them to report serial numbers. The facilities are located across Europe in France, Italy, Sweden, Spain, Germany, the UK and Portugal, as well as in India.

Staffan Widengren, director corporate projects, said, “Recipharm has been very committed to meeting compliance deadlines, establishing a dedicated task force three years ago. A lot of time and effort has gone into our preparations so it’s rewarding to report that we are ready, especially ahead of the enforcement date. Standardising our serialisation capabilities has enabled us to provide a seamless and flexible service to our customers, across multiple markets.”